Novel bacteriophage and therapeutic agent for bacterial endophthalmitis

Abstract

The objective of the present invention is to provide a novel bacteriophage useful for treating bacterial endophthalmitis and a therapeutic agent for bacterial endophthalmitis comprising the novel bacteriophage. The therapeutic agent for bacterial endophthalmitis according to the present invention is characterized in comprising 1 or more bacteriophages selected from the group essentially consisting of Myoviridae Spounavirinae phiEF7H (accession number: NITE BP-02886), Myoviridae Spounavirinae phiEF19G (accession number: NITE BP-02887), Myoviridae Spounavirinae phiEF14H1 (accession number: NITE BP-02888), and mutants thereof.

1 - 7 . (canceled) 
     
     
         8 .  Myoviridae Spounavirinae  phiEF7H (accession number: NITE BP-02886). 
     
     
         9 .  Myoviridae Spounavirinae  phiEF19G (accession number: NITE BP-02887). 
     
     
         10 .  Myoviridae Spounavirinae  phiEF14H1 (accession number: NITE BP-02888). 
     
     
         11 . A treatment agent for bacterial endophthalmitis,
 comprising 1 or more bacteriophages selected from the group essentially consisting of  Myoviridae Spounavirinae  phiEF7H (accession number: NITE BP-02886),  Myoviridae Spounavirinae  phiEF19G (accession number: NITE BP-02887),  Myoviridae Spounavirinae  phiEF14H1 (accession number: NITE BP-02888), and mutants thereof,   wherein the mutant comprises any one of the following base sequences:   (1) a base sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 having deletion, substitution and/or addition of 1 or more and 1500 or less of bases, wherein the mutant having the base sequence exhibits a bacteriolytic action against a bacterium causing bacterial endophthalmitis;   (2) a base sequence having a sequence identity of 99.9% or more to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, wherein the mutant having the base sequence exhibits a bacteriolytic action against a bacterium causing bacterial endophthalmitis.   
     
     
         12 . The treatment agent for bacterial endophthalmitis according to  claim 11 , wherein the number of the mutation of the deletion, substitution and/or addition is 800 or less, and the sequence identity is 99.95% or more. 
     
     
         13 . The treatment agent for bacterial endophthalmitis according to  claim 11 , further comprising 1 or more bacteriophages selected from the group essentially consisting of  Myoviridae Spounavirinae  phiEF24C,  Myoviridae Spounavirinae  phiEF24C-P2, and mutants thereof. 
     
     
         14 . The treatment agent for bacterial endophthalmitis according to  claim 11 , wherein the treatment agent is a liquid medicine.